- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06743399
Care Bundle Applıcation in the Prevention of Phlebitis (Non-randomized)
The Effect of Evidence-Based Care Bundle Applıcatıon in the Prevention of Peripheral Venous Catheter-Related Phlebitis Development
Study Overview
Status
Detailed Description
Peripheral venous catheterization (PVC) is a procedure that involves the insertion of a cannula into the lumen of a vein through the patient's skin. It is among the most commonly performed invasive nursing interventions in hospitalized patients. PVC is utilized at various stages of care for approximately 80% of patients during their hospital stay, serving multiple purposes, including meeting their fluid requirements, maintaining fluid-electrolyte balance, administering pharmacological treatments, transfusing blood and blood products, providing total parenteral nutrition (TPN), ensuring vascular access, and monitoring hemodynamic parameters.
When performed appropriately, PVC is a valuable procedure that can be lifesaving for patients. However, improper application or inadequate catheter care can lead to significant local complications, such as infiltration, extravasation, and hemorrhage, as well as systemic complications, including embolism, infection, and circulatory overload. Among these complications, phlebitis, characterized by pain and tenderness along the vein due to inflammation of the intima layer, is particularly common. A variety of factors contribute to the development of phlebitis. Individual factors include advanced age, gender, neutropenia, malnutrition, cancer, cardiovascular diseases, immunosuppression, existing infections, diabetes, smoking, confusion, dementia, and impaired consciousness. Mechanical factors involve the type and size of catheter, the duration of catheter placement, and the anatomical site of insertion. Chemical factors encompass the pH and osmolarity of fluids, as well as the introduction of antiseptic solutions into the vein. Additionally, procedural factors such as the frequency of set changes, maintenance of aseptic conditions, care of the catheter site, and the type of dressing materials used also play a significant role in the incidence of phlebitis.
The Infusion Nurses Society (INS) and the Infusion Nurses Association (INA) recommend that the incidence of phlebitis in a specified patient population should remain below 5%. However, the literature indicates that the incidence of phlebitis varies widely, with reported rates ranging from 1.25% to 80%. In specific studies conducted in our country, the incidence of phlebitis has been reported to be considerably higher, ranging from 17% to 67%. This variability may be attributed to differences in healthcare practices, infection control measures, and patient demographics.
Phlebitis is a common but preventable complication in clinical practice. Enhancing the quality of care to prevent such complications has led to the prominence of care bundles, which are structured sets of clinical practices aimed at preventing specific complications or improving particular clinical outcomes. The care bundle approach entails the simultaneous and complete implementation of scientifically validated practices, applied in a step-by-step manner. Resarch indicates that the application of these practices as a cohesive whole yields better outcomes compared to their individual application. Each component of a care bundle should consist of commonly accepted practices that are supported by evidence, preferably derived from randomized controlled trials classified at evidence levels I and II. Maintaining high compliance with care bundle protocols enhances their effectiveness and overall quality of care, ultimately contributing to reductions in both mortality and morbidity.
Researches that the application of care bundles leads to improved clinical outcomes. Studies have been demonstrated implementation of care bundles significantly reduces the incidence of ventilator-related pneumonia (VRP) and central venous catheterization-related blood circulation infections (CVCR-BCI).
Null Hypothesis (H0) = The application of evidence-based care bundles does not affect the prevention of the development of peripheral venous catheter-related phlebitis.
Alternative Hypothesis (H₁) = The application of evidence-based care bundles positively affects the prevention of peripheral venous catheter-related phlebitis.
In this study, a non-randomized controlled trial was designed and executed, incorporating both control and experimental groups. The methodology followed the guidelines of the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for case-control studies.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Karaman, Turkey, 70000
- Karamanoğlu Mehmetbey Üniversitesi Sağlık Hizmetleri MYO
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Received inpatient treatment for at least 72 hours Internal Medicine/Wound Care Clinic and Neurology/Neurosurgery clinics,
- PVK is applied in specified clinics,
- No existing phlebitis,
- No bleeding, clotting or circulatory disorders (learned from patient records),
- Not receiving immunosuppressive, chemotherapy and radiotherapy treatments,
- 18 years and above,
- Patients who volunteered to participate in the study were included in the study.
Exclusion Criteria:
- Transferred to another clinic,
- Died during the research process,
- (For experimental group patients) Failure to fully comply with the care package,
- Patients who wanted to leave the study after agreeing to participate in the study were excluded from the study.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Experimental Group
The experimental group included patients who received training, follow-up care, and the care bundle.
Patients provided consent, completed demographic forms, and their PVC applications were assessed daily using the "Phlebitis Care Bundle Follow-up Form."
Full compliance with all care bundle parameters was required, and non-compliant patients were excluded.
Nurses received feedback, and phlebitis symptoms were recorded daily.
Monitoring continued until catheter removal or patient discharge.
Data collection took place daily from 09:00-12:00, lasting about 2.5 hours.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Phlebitis Care Bundle Clinical Follow-up Form
Time Frame: The evaluation took an average of 6 months until the completion of the study.
|
This form was developed to track and record the daily application of nursing interventions from the evidence-based care bundle designed to prevent the development of PVC-related phlebitis.
|
The evaluation took an average of 6 months until the completion of the study.
|
|
Phlebitis Evaluation Scale
Time Frame: The evaluation took an average of 6 months until the completion of the study.
|
The Phlebitis Evaluation Scale developed by the Intravenous Nursing Society (2006) was used to assess phlebitis symptoms in the area where PVC was placed.
The scale ranges from 0 to 4, where 0 indicates no symptoms, 1 indicates redness and/or pain in the catheter entry point, 3 indicates redness, pain, and/or edema at the catheter entry point, red line, and palpation of the vein as a cable, and 4 includes symptoms such as redness, pain, and/or edema at the catheter entry point, red line, palpation of the vein as a cable, being longer than 2.5 cm, and purulent drainage.
The researcher observes the PVC area and determines the degree of phlebitis.
|
The evaluation took an average of 6 months until the completion of the study.
|
|
Peripheral Venous Catheter Observation
Time Frame: The evaluation took an average of 6 months until the completion of the study.
|
The form, created by the researcher, was designed to daily record the phlebitis symptoms and degree included in the Phlebitis Evaluation Scale
|
The evaluation took an average of 6 months until the completion of the study.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Karamanoglu Mehmetbey U
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on All Patients with Peripheral Venous Catheters
-
Shandong Branden Med.Device Co.,LtdThird Affiliated Hospital, Sun Yat-Sen UniversityNot yet recruitingPatients Requiring Peripherally Inserted Central Venous Catheters
-
TeleflexCompletedAdult Patients With Peripherally Inserted Central CathetersUnited States
-
University Hospital OstravaRecruitingAdult Patients With Mid-term or Long-term Venous AccessCzechia
-
Universitat Pompeu FabraUnknownPatients With Unilateral Peripheral Vestibular DeficitsSpain
-
Centre Hospitalier Universitaire, AmiensUnknownObesity | Central Venous CathetersFrance
-
Policlinico HospitalCompletedCentral Venous Catheter Thrombosis | Intensive Care Unit | Thrombosis, Venous | Central Venous CathetersItaly
-
First Affiliated Hospital Xi'an Jiaotong UniversityCompletedPancreatic Tumor Patients Who Consecutively Underwent Minimally Invasive or Open Pancreatic Surgery With Venous ReconstructionChina
-
Tampere University HospitalTampere University; Aalto University; Åbo Akademi UniversityCompletedPatients With Lower Extremity Venous Ulcers | Patients With Localized EdemaFinland
-
Second Affiliated Hospital, School of Medicine,...UnknownVenous Thrombosis Due to Central Venous Access Device (Disorder) | Prophylactic Anticoagulation | Patients With TumorChina
-
George Washington UniversityJohns Hopkins UniversityCompletedPatients With Peripheral Intravenous Access LinesUnited States